Literature DB >> 16396863

Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial.

Lex W Doyle1, Peter G Davis, Colin J Morley, Andy McPhee, John B Carlin.   

Abstract

OBJECTIVE: Postnatal corticosteroid therapy is controversial. The aim of this study was to determine the short-term effects of low-dose dexamethasone treatment among chronically ventilator-dependent neonates.
METHODS: Very preterm (gestational age: <28 weeks) or extremely low birth weight (birth weight: <1000 g) infants who were ventilator dependent after the first 1 week of life were eligible and were assigned randomly to receive masked dexamethasone (0.89 mg/kg over 10 days) or saline placebo. Data on ventilator and oxygen requirements and deaths were recorded.
RESULTS: Seventy infants were recruited from 11 centers, at a median age of 23 days. More infants were extubated successfully by 10 days of treatment in the dexamethasone group (60%, 21 of 35 patients) than in the control group (12%, 4 of 34 patients) (odds ratio [OR]: 11.2; 95% confidence interval [CI]: 3.2-39.0). Ventilator and oxygen requirements improved substantially, and the duration of intubation was shorter. There was little evidence for a reduction in either the mortality rate (dexamethasone group: 11%; control group: 20%; OR: 0.52; 95% CI: 0.14-1.95) or the rate of oxygen dependence at 36 weeks (dexamethasone group: 85%; control group: 91%; OR: 0.58; 95% CI: 0.13-2.66). There were no obvious effects of low-dose dexamethasone on blood glucose concentrations, blood pressure, or other complications. No infant experienced intestinal perforation.
CONCLUSIONS: Low-dose dexamethasone treatment after the first 1 week of life clearly facilitates extubation and shortens the duration of intubation among ventilator-dependent, very preterm/extremely low birth weight infants, without any obvious short-term complications. Combined with recent evidence that infants at very high risk of bronchopulmonary dysplasia may benefit in the long term, our study reopens debate regarding the role of low-dose, late postnatal, corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16396863     DOI: 10.1542/peds.2004-2843

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  48 in total

1.  Glucocorticoids exacerbate hypoxia-induced expression of the pro-apoptotic gene Bnip3 in the developing cortex.

Authors:  U S Sandau; R J Handa
Journal:  Neuroscience       Date:  2006-11-15       Impact factor: 3.590

Review 2.  Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?

Authors:  Eric C Eichenwald; Ann R Stark
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09       Impact factor: 5.747

Review 3.  Review of the antenatal and postnatal use of steroids.

Authors:  Julie Bartholomew; Lajos Kovacs; Apostolos Papageorgiou
Journal:  Indian J Pediatr       Date:  2014-03-30       Impact factor: 1.967

4.  Stopping the swinging pendulum of postnatal corticosteroid use.

Authors:  Sara B Demauro; Kevin Dysart; Haresh Kirpalani
Journal:  J Pediatr       Date:  2014-01       Impact factor: 4.406

Review 5.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

6.  Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes.

Authors:  Nehal A Parikh; Kathleen A Kennedy; Robert E Lasky; Georgia E McDavid; Jon E Tyson
Journal:  J Pediatr       Date:  2012-11-08       Impact factor: 4.406

Review 7.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

8.  Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia.

Authors:  Jonathan L Slaughter; Michael R Stenger; Patricia B Reagan
Journal:  Pediatrics       Date:  2013-03-11       Impact factor: 7.124

9.  Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants.

Authors:  Deanne Wilson-Costello; Michele C Walsh; John C Langer; Ronnie Guillet; Abbot R Laptook; Barbara J Stoll; Seetha Shankaran; Neil N Finer; Krisa P Van Meurs; William A Engle; Abhik Das
Journal:  Pediatrics       Date:  2009-02-09       Impact factor: 7.124

Review 10.  A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.

Authors:  Ricardo M Fernandes; Johanna H van der Lee; Martin Offringa
Journal:  BMC Pediatr       Date:  2009-12-13       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.